Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North Carolina and Austin, Texas. Shattuck Labs Inc. is based in Austin, United States.
| Revenue (Most Recent Fiscal Year) | $1.00M |
| Net Income (Most Recent Fiscal Year) | $-48.81M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.78 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -5256.80% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -43.57% |
| Return on Assets (Trailing 12 Months) | -40.90% |
| Current Ratio (Most Recent Fiscal Quarter) | 27.59 |
| Quick Ratio (Most Recent Fiscal Quarter) | 27.59 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.75 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.12 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.70 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.51 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 76.68M |
| Free Float | 69.94M |
| Market Capitalization | $587.37M |
| Average Volume (Last 20 Days) | 0.91M |
| Beta (Past 60 Months) | 1.08 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.79% |
| Percentage Held By Institutions (Latest 13F Reports) | 58.74% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |